Bristol-Myers Squibb Company

NYSE:BMY

Drug Manufacturers - General

Healthcare
$59.56 -2.57%

-$1.42 today

Market cap
$121.75B
Beta
0.24
P/E (TTM)
15.1
EPS (TTM)
$3.56
Dividend yield
4.64%
52W Low $42.52High $62.89

Volume 9.54M

Average 11.50M

BMY Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Bristol-Myers Squibb CompanyNYSE: BMY

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents falls 30.8% from a year ago

Cash & equivalents stood at $8.72B at the end of Q2 FY2026, down 30.8% from a year earlier and down 8.9% from the prior quarter. Over 3 fiscal years it compounded at +3.8% a year.

Context

  • Cash & equivalents amounted to 10.0% of total assets at the end of Q2 FY2026, down 3.4 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -30.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$8.72B-8.9% QoQ
Last fiscal yearDec 2025
$10.21B-1.3% YoY
Year agoJun 2025
$12.6B-30.8% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.8%——
1 year-1.3%——
3-year CAGR+3.8%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
10.21B USD
Year-over-year change
-1.3%
4-year CAGR
-7.6%

Cash & Equivalents vs competitors

How BMY compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -30.8% is the 8th highest of 11, against a peer median of -5.0%.
  • Cash & equivalents amounts to 10.0% of total assets for BMY, versus a peer median of 6.2%.
BMY Competitors
Cash & Equivalents for BMY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
JNJJohnson & JohnsonSep 2026$16.91B USD-7.2%+15.2%8.6%
AMGNAmgen Inc.Jun 2026$13.99B USD+74.3%+6.2%14.6%
LLYEli Lilly and CompanyJun 2026$8.89B USD+163.3%+51.3%6.2%
BMYBristol-Myers Squibb CompanyJun 2026$8.72B USD-30.8%+3.8%10.0%
AZNAstraZeneca PLCSep 2026$7.92B USD-2.7%-2.5%6.6%
NVSNovartis AGJun 2026$7.62B USD+14.4%+15.0%6.2%
MRKMerck & Co., Inc.Jun 2026$6.85B USD-14.5%+4.7%5.3%
ABBVAbbVie Inc.Jun 2026$6.57B USD+1.6%-17.2%4.9%
GILDGilead Sciences, Inc.Jun 2026$3.18B USD-38.2%+11.8%6.4%
GSKGSK plcJun 2026£3.09B GBP-37.4%-3.1%5.0%
PFEPfizer Inc.Jun 2026$976M USD-40.4%+40.0%0.5%
Peer median (excluding BMY) —-5.0%+9.0%6.2%

Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents13.98B9.12B11.46B10.35B10.21B
Short-term Investments3.24B130M816M513M464M
Net Receivables12.52B13.94B15.26B14.42B14.53B
Inventory2.1B2.34B2.66B2.56B2.69B
Other Current Assets1.43B1.74B1.56B1.94B1.5B
Total Current Assets33.26B27.27B31.77B29.78B29.39B
Property, Plant & Equipment (Net)6.97B7.48B8.04B8.36B9.13B
Goodwill20.5B21.15B21.17B21.72B21.75B
Intangible Assets42.78B36.36B27.49B23.64B19.1B
Long-term Investments2.71B2.19B2.5B2.51B2.51B
Tax Assets1.44B1.34B2.77B4.24B5.38B
Other Non-current Assets1.66B1.04B1.43B2.36B2.78B
Total Non-current Assets76.05B69.55B63.39B62.82B60.65B
Total Assets109.31B96.82B95.16B92.6B90.04B
Account Payables2.95B3.04B3.26B3.6B3.58B
Short-term Debt4.95B4.26B3.12B2.05B2.26B
Tax Payables754M942M1.37B1.51B979M
Deferred Revenue00000
Other Current Liabilities11.48B11.99B12.79B14.6B14.63B
Total Current Liabilities21.87B21.89B22.26B23.77B23.42B
Long-term Debt39.61B35.06B36.65B47.6B42.85B
Deferred Tax Liabilities4.5B2.17B338M369M222M
Deferred Revenue (Non-current)326M283M300M230M169M
Other Non-current Liabilities6.13B5.05B4.59B2.87B3.05B
Total Non-current Liabilities51.44B43.81B43.41B52.44B48.12B
Total Liabilities73.31B65.7B65.67B76.22B71.53B
Common Stock292M292M292M292M292M
Retained Earnings23.82B25.5B28.77B14.91B16.9B
Accumulated OCI(1.27B)(1.28B)(1.55B)(1.24B)(1.52B)
Other Stockholders Equity00000
Minority Interest60M57M55M53M33M
Total Equity36.01B31.12B29.49B16.39B18.51B
Total Debt45.6B40.72B41.46B51.2B47.14B
Net Debt31.62B31.59B30B40.85B36.93B

Bristol-Myers Squibb Company

NYSE:BMY

Intrinsic Alpha fair value

Locked

Current Price

$59.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.